Results 211 to 220 of about 233,485 (260)

Pharmacokinetics: Dose‐Dependent Changes

The Journal of Clinical Pharmacology, 1986
Stable‐isotope tracer methods are described for answering the following questions about a drug: (1) Does the drug exhibit dose‐dependent changes in pharmacokinetic properties? (2) What are the drug's Michaelis constant (Km) and maximum velocity (Vmax) for enzymatic biotransformation; (3) Are the dose‐dependent pharmacokinetic changes great enough to be
T R, Browne, D J, Greenblatt, J E, Evans, G K, Szabo, B A, Evans, G E, Schumacher   +5 more
openaire   +2 more sources

Dose-dependent melanonychia by mitoxantrone

Multiple Sclerosis Journal, 2009
We report an unusual case of a 43-year old female patient suffering from multiple sclerosis, who was treated with mitoxantrone. Few weeks after treatment initiation a hyperpigmentation of the patient’s left thumb and index was noted.
C, Reinsberger, S G, Meuth, H, Wiendl
openaire   +2 more sources

Dose dependent pharmacokinetics of midazolam

European Journal of Clinical Pharmacology, 1985
The pharmacokinetics of midazolam and 1-hydroxymethylmidazolam were investigated following oral administration of 7.5, 15 and 30 mg doses of midazolam in solution to 12 healthy subjects. Compared to the 7.5 mg dose, the Cmax and AUC parameters of both midazolam and 1-hydroxymethylmidazolam increased proportionally after the 15 mg dose and more than ...
L D, Bornemann, B H, Min, T, Crews, M M, Rees, H P, Blumenthal, W A, Colburn, I H, Patel   +6 more
openaire   +2 more sources

Alcoholic Cardiomyopathy: Is It Dose‐Dependent?

Congestive Heart Failure, 2002
Alcohol is a known myocardial depressant. In a dose‐dependent fashion, one can show progressive decline in left ventricular systolic function. This observation has been used to implicate alcohol as a major cause of up to 30% of all dilated cardiomyopathies.
William K, Lee, Timothy J, Regan
openaire   +2 more sources

Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria

Bone, 2016
Deferasirox is an oral iron chelator used widely in the treatment of thalassemia major and other transfusion-dependent hemoglobinopathies. Whilst initial long-term studies established the renal safety of deferasirox, there are now increasing reports of hypercalciuria and renal tubular dysfunction.
Phillip Wong, Kevan Polkinghorne, Peter G. Kerr, James C.G. Doery, Matthew T. Gillespie, I. Larmour, Peter J. Fuller, Donald K. Bowden, Frances Milat   +8 more
openaire   +2 more sources

Dose-dependent metabolism and dose setting in chronic studies

Toxicology Letters, 1992
Because of the expense involved in conducting chronic studies, limited numbers of animals and dose groups are used. This has given rise to the practice of including as one of the dose groups the "Maximum Tolerated Dose" (MTD). This dose is operationally defined as the highest dose which can be administered to animals without adversely affecting their ...
J S, Bus, R H, Reitz
openaire   +2 more sources

Dose dependence and dose-rate dependence of the optically stimulated luminescence signal

Journal of Applied Physics, 2001
The expected behavior of the dose dependence of the optically stimulated luminescence (OSL) signal has been studied using numerical simulation. A simple model of one trapping state and one kind of recombination center is presented, and the sequence of sets of simultaneous differential equations governing the processes during excitation, relaxation, and
R. Chen, P. L. Leung
openaire   +1 more source

Dose-dependent uricosuric effect of ambroxol

European Journal of Clinical Pharmacology, 1993
Ambroxol is known to promote bronchial secretion and is used as an expectorant. Previous studies had suggested that high doses of ambroxol could reduce the plasma uric acid concentration. The present study was undertaken to confirm this finding, to determine its dose-response relationship and to identify the underlying mechanism of action.
B, Oosterhuis, G, Storm, P J, Cornelissen, C A, Su, F A, Sollie, J H, Jonkman   +5 more
openaire   +2 more sources

Dose dependent pharmacokinetics of albendazole in human

Biopharmaceutics & Drug Disposition, 2002
AbstractPharmacokinetics of albendazole sulphoxide (ABZ‐SO) in three different single oral doses of albendazole (ABZ) (400, 800 and 1200 mg) was studied in 10 healthy human volunteers in a double blind three‐way crossover design. The serum levels of albendazole main metabolite, albendazole sulphoxide (ABZ‐SO), were analysed by a modified high‐pressure ...
A, Mirfazaelian, M R, Rouini, S, Dadashzadeh   +2 more
openaire   +2 more sources

Dose-dependent transitions in mechanisms of toxicity

Toxicology and Applied Pharmacology, 2004
Scientists and decision makers from all sectors agree that risk assessments should be based on the best available science. Several years ago, the Health and Environmental Sciences Institute (HESI), a global branch of the International Life Sciences Institute (ILSI), identified the need for better scientific understanding of dose-dependent transitions ...
William, Slikker, Melvin E, Andersen, Matthew S, Bogdanffy, James S, Bus, Steven D, Cohen, Rory B, Conolly, Raymond M, David, Nancy G, Doerrer, David C, Dorman, David W, Gaylor, Dale, Hattis, John M, Rogers, R Woodrow, Setzer, James A, Swenberg, Kendall, Wallace   +14 more
openaire   +2 more sources